Clinical Evaluation of Novel Natural Polysaccharides Sacran as a Skincare Material for Atopic Dermatitis Patients

• DOI: 10.4236/jcdsa.2016.61002
• Publication Date: 2016-03-02T02:22:11Z
• Authors: Satoshi Fukushima; Keiichi Motoyama; Yuki Tanida; Taishi Higashi; Yoichi Ishitsuka; Yuki Kondo; Tetsumi Irie; Takumi Tanaka; Hironobu Ihn; Hidetoshi Arima
• Keywords: SCORAD; Itching

Atopic dermatitis is a skin disease characterized by inflammation, pruritus, and chronic or relapsing eczematous lesions. Recently, ampholytic polysaccharide sacran has attracted particular focus of attention as novel biomaterial. In the present study, we investigated effect solution on atopic in clinical study. Almost all average scores for symptoms each patient treated with solutions were improved. addition, sleep disorder itching also significantly ameliorated treatment 4 weeks, compared those initial states. immatured dermal model stimulated 2,4-dinitrofluorobenzene (DNFB), markedly down-regulated inflammatory cytokine chemokine mRNA levels such MCP-1, TNF-α, IL-1β, IL-6 mRNAs, that DNFB alone. Furthermore, suppressed expression TNF-α COX-2 RAW264.7 cells, murine macrophage-like cell line, phorbol-12-myristate-13-acetate (PMA). RBL-2H3 rat basophilic leukemia lowered β-hexosaminidase release, indicating suppression allergic response. These results suggest may have potential to improve through impairment production mRNA.